Daito Pharmaceutical Co.,Ltd. (TYO:4577)
1,348.00
+4.00 (0.30%)
Jan 21, 2026, 3:30 PM JST
Daito Pharmaceutical Revenue
Daito Pharmaceutical had revenue of 12.13B JPY in the quarter ending November 30, 2025, with 1.88% growth. This brings the company's revenue in the last twelve months to 51.20B, up 8.09% year-over-year. In the fiscal year ending May 31, 2025, Daito Pharmaceutical had annual revenue of 50.64B with 7.99% growth.
Revenue (ttm)
51.20B
Revenue Growth
+8.09%
P/S Ratio
0.77
Revenue / Employee
47.72M
Employees
1,073
Market Cap
39.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 50.64B | 3.75B | 7.99% |
| May 31, 2024 | 46.90B | 1.79B | 3.98% |
| May 31, 2023 | 45.10B | 1.64B | 3.77% |
| May 31, 2022 | 43.46B | -5.25B | -10.78% |
| May 31, 2021 | 48.71B | 3.72B | 8.27% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KYORIN Pharmaceutical | 133.68B |
| Mochida Pharmaceutical | 109.05B |
| Zeria Pharmaceutical | 84.85B |
| ASKA Pharmaceutical Holdings | 67.02B |
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Fuji Pharma | 51.68B |
| Koa Shoji Holdings | 24.19B |